Never Run Out Of Buyers To Sell To.

Antag Therapeutics is a biotechnology company pioneering personal and flexible obesity treatment through GIP receptor antagonism. Antag’s lead molecule AT-7687 is specifically designed to target and deactivate the GIP receptor, a genetically-validated pathway that contributes to fat storage, insulin resistance, and metabolic dysfunction – and is mechanistically distinct from GLP-1 therapies. Antag’s GIPR antagonist approach stems from the work of the esteemed research teams of Professors Jens Juul Holst and Mette Rosenkilde, two co-founders of the business. Antag’s vision is that all people…
Annual Revenue$10M to $25M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.